Astel­las wins pri­or­i­ty re­view for AML drug; Take­da share­hold­ers re­volt against $62B Shire deal

→ Astel­las has won a pri­or­i­ty re­view for its FLT3 drug gilter­i­tinib for treat­ing acute myeloid leukemia. The Japan­ese phar­ma com­pa­ny, which has been earn­ing some added at­ten­tion as a pos­si­ble takeover tar­get, says the fast-paced FDA re­view was based on da­ta from its on­go­ing piv­otal study. A mar­ket­ing de­ci­sion is due No­vem­ber 29. The ther­a­py al­so has Japan’s Saki­ga­ki des­ig­na­tion.

→ A group of Take­da share­hold­ers has been ag­i­tat­ing for a vote on the $62 bil­lion Shire takeover. They say that the buy­out will dam­age Take­da, but the board is op­posed to the vote and wants to see the deal go through.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER